ABAndrew T. Bockus

Andrew T. Bockus

*This is an algorithmically generated author record based on publicly available information.

Andrew T. Bockus has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Bernard Levin

    Circle Pharma, 169 Harbor Way, South San Francisco, California 94080, United States

    3 shared publications
  • Breena Fraga-Walton

    Circle Pharma, 169 Harbor Way, South San Francisco, California 94080, United States

    3 shared publications
  • Bryan M. Lent

    Circle Pharma, 169 Harbor Way, South San Francisco, California 94080, United States

    3 shared publications
  • Constantine Kreatsoulas

    Circle Pharma, 169 Harbor Way, South San Francisco, California 94080, United States

    3 shared publications
  • Dalena Hoang

    Circle Pharma, 169 Harbor Way, South San Francisco, California 94080, United States

    3 shared publications
  • Daphne He

    Circle Pharma, 169 Harbor Way, South San Francisco, California 94080, United States

    3 shared publications

Latest Publications

  • Open Access

    Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1–S-Checkpoint-Compromised Cancers

    by Justin A. Shapiro, Nathan J. Dupper, Breena Fraga-Walton, Andrew T. Bockus, Siegfried S.F. Leung, Kai Yang, Chinmay Bhatt, Megan K. DeMart, Miguel P. Baldomero, Luis Hernandez, et al.

    Cyclins A and B bind and activate their cognate cyclin-dependent kinase (CDK) to regulate progression through the S and G2/M phases of the cell cycle, respectively. Cyclins recruit substrates and regulators through the binding of an RxL motif with a Hydrophobic Patch (HP) on the cyclin surface. We recently disclosed the first class of passively permeable macrocyclic peptides that bind to the HP of both Cyclin A and Cyclin B and selectively kill cancer cells with high E2F activity. We used a lead example to demonstrate in vivo tumor regression in cell-line-derived xenograft models of small-cell lung cancer (SCLC) via intraperitoneal dosing. Here we describe the optimization of this series for drug-like properties and oral bioavailability, resulting in the discovery of a lead compound, which demonstrates tumor regression in CDX models of SCLC via oral dosing. We are currently evaluating Cyclin A/B inhibition in a Phase 1 clinical trial.


  • Open Access

    Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors

    by Shilpa Singh, Catherine E. Gleason, Min Fang, Yasmin N. Laimon, Vishal Khivansara, Shanhai Xie, Yavuz T. Durmaz, Aniruddha Sarkar, Kenneth Ngo, Varunika Savla, et al.

    Small-cell lung cancers (SCLCs) contain near-universal loss-of-function mutations in RB1 and TP53, compromising the G1–S checkpoint and leading to dysregulated E2F activity1. Other cancers similarly disrupt the G1–S checkpoint through loss of CDKN2A or amplification of cyclin D or cyclin E, also resulting in excessive E2F activity2,3. Although E2F activation is essential for cell cycle progression, hyperactivation promotes apoptosis4,5,6,7,8,9, presenting a therapeutic vulnerability. Cyclin proteins use a conserved hydrophobic patch to bind to substrates bearing short linear RxL motifs10,11,12,13. Cyclin A represses E2F through an RxL-dependent interaction10,14, which, when disrupted, hyperactivates E2F15. However, this substrate interface has remained difficult to target. Here we developed cell-permeable, orally bioavailable macrocyclic peptides that inhibit RxL-mediated interactions of cyclins with their substrates. Dual inhibitors of cyclin A and cyclin B RxL motifs (cyclin A/Bi) selectively kill SCLC cells and other cancer cells with high E2F activity. Genetic screens revealed that cyclin A/Bi induces apoptosis through cyclin B- and CDK2-dependent spindle assembly checkpoint activation. Mechanistically, cyclin A/Bi hyperactivates E2F and cyclin B by blocking cyclin A–E2F and cyclin B–MYT1 RxL interactions. Notably, cyclin A/Bi promoted the formation of neomorphic cyclin B–CDK2 complexes, which drive spindle assembly checkpoint activation and mitotic cell death. Finally, orally administered cyclin A/Bi showed robust anti-tumour activity in chemotherapy-resistant SCLC patient-derived xenografts. These findings reveal gain-of-function mechanisms through which cyclin A/Bi triggers apoptosis and support their development for E2F-driven cancers.


  • Open Access

    Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity

    by Andrew T. Bockus, Siegfried S. F. Leung, Breena Fraga-Walton, Miguel P. Baldomero, Luis Hernandez, Nathan J. Dupper, Justin A. Shapiro, Bryan M. Lent, David C. Spellmeyer, Megan K. DeMart, et al.

    The cyclin-dependent kinase (CDK)/retinoblastoma protein (RB)/early region 2 binding factor (E2F) axis forms the core transcriptional machinery driving cell cycle progression. Alterations in RB1 or other pathway members occur in many cancers, resulting in heightened oncogenic E2F activity. The activity of E2F is regulated by RxL-mediated binding to the hydrophobic patch (HP) of Cyclin A; blocking this interaction results in the hyperactivation of E2F and synthetic lethality in E2F-driven tumors. While mechanistically differentiated and potentially more selective than blocking CDK activity (e.g., CDK2 or CDK4 inhibitors), the Cyclin A/E2F RxL interaction was deemed undruggable. Utilizing structure-based design, we have discovered a family of cell-permeable macrocyclic Cyclin A/B RxL inhibitors that show potent and selective activity against RB1/E2F-dysregulated cancer cell lines. Lead compound 34 demonstrated proof-of-concept efficacy via intraperiotoneal (IP) administration in mouse cell line-derived xenograft (CDX) tumor models.